TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Arthroscopic Partial Resection for the Degenerative Tear of the Medial Meniscus of a Knee
Brief Summary: Degenerative meniscal tears are the most common etiology for knee pain, swelling and loss of function. Partial arthroscopic meniscectomy is the most common orthopaedic procedure to treat meniscal tears. Improvements have been reported both after arthroscopy and with conservative treatment, however no direct comparison exist. Accordingly, the aim of this study is to assess the efficacy of arthroscopic partial meniscectomy for the treatment of degenerative tear of medial meniscus of the knee using a double-blind, placebo controlled, randomised trial.


Options:
A: Arm Label: Arthroscopic Partial Meniscectomy; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic Partial Meniscectomy | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: PROCEDURE; Name: Arthroscopic Partial Meniscectomy; Assigned to Arm(s): Arthroscopic Partial Meniscectomy | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Physical Therapy
B: Arm Label: Surgical; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial menisectomy, Other: Postoperative rehabilitative physical therapy | Arm Label: Nonoperative; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard physical therapy | Intervention Type: PROCEDURE; Name: Arthroscopic partial menisectomy; Assigned to Arm(s): Surgical | Intervention Type: OTHER; Name: Standard physical therapy; Assigned to Arm(s): Nonoperative | Intervention Type: OTHER; Name: Postoperative rehabilitative physical therapy; Assigned to Arm(s): Surgical
C: Arm Label: Operative (O); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Operative (partial arthroscopy) | Arm Label: Conservative (K); Type: SHAM_COMPARATOR; Interventions: Procedure: Conservative (diagnostic arthroscopy) | Intervention Type: PROCEDURE; Name: Operative (partial arthroscopy); Assigned to Arm(s): Operative (O) | Intervention Type: PROCEDURE; Name: Conservative (diagnostic arthroscopy); Assigned to Arm(s): Conservative (K)
D: Arm Label: Arthroscopic partial meniscectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopic partial meniscectomy | Arm Label: Arthroscopy (diagnostic); Type: SHAM_COMPARATOR; Interventions: Procedure: Arthroscopy (diagnostic) | Intervention Type: PROCEDURE; Name: Arthroscopic partial meniscectomy; Assigned to Arm(s): Arthroscopic partial meniscectomy | Intervention Type: PROCEDURE; Name: Arthroscopy (diagnostic); Assigned to Arm(s): Arthroscopy (diagnostic)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Arthroscopic Partial Resection for the Degenerative Tear of the Medial Meniscus of a Knee
Brief Summary: Degenerative meniscal tears are the most common etiology for knee pain, swelling and loss of function. Partial arthroscopic meniscectomy is the most common orthopaedic procedure to treat meniscal tears. Improvements have been reported both after arthroscopy and with conservative treatment, however no direct comparison exist. Accordingly, the aim of this study is to assess the efficacy of arthroscopic partial meniscectomy for the treatment of degenerative tear of medial meniscus of the knee using a double-blind, placebo controlled, randomised trial.


Options:
A: Arm Label: Surgical; Type: EXPERIMENTAL; Interventions: Procedure: Arthroscopic partial menisectomy, Other: Postoperative rehabilitative physical therapy | Arm Label: Nonoperative; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard physical therapy | Intervention Type: PROCEDURE; Name: Arthroscopic partial menisectomy; Assigned to Arm(s): Surgical | Intervention Type: OTHER; Name: Standard physical therapy; Assigned to Arm(s): Nonoperative | Intervention Type: OTHER; Name: Postoperative rehabilitative physical therapy; Assigned to Arm(s): Surgical
B: Arm Label: Operative (O); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Operative (partial arthroscopy) | Arm Label: Conservative (K); Type: SHAM_COMPARATOR; Interventions: Procedure: Conservative (diagnostic arthroscopy) | Intervention Type: PROCEDURE; Name: Operative (partial arthroscopy); Assigned to Arm(s): Operative (O) | Intervention Type: PROCEDURE; Name: Conservative (diagnostic arthroscopy); Assigned to Arm(s): Conservative (K)
C: Arm Label: PRP; Type: EXPERIMENTAL; Interventions: Biological: Platelet rich plasma | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Platelet rich plasma; Assigned to Arm(s): PRP
D: Arm Label: Arthroscopic microfracture (MF); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopic microfracture (MF) | Arm Label: Arthroscopic debridement (AD); Type: SHAM_COMPARATOR; Interventions: Procedure: Arthroscopic debridement (AD) | Intervention Type: PROCEDURE; Name: Arthroscopic microfracture (MF); Assigned to Arm(s): Arthroscopic microfracture (MF) | Intervention Type: PROCEDURE; Name: Arthroscopic debridement (AD); Assigned to Arm(s): Arthroscopic debridement (AD)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension
Brief Summary: Study to determine the long term safety of tadalafil in patients with increased blood pressure in the blood vessel that carries blood from the right heart to the lungs and to see if it will keep the disease from getting worse.


Options:
A: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A
C: Arm Label: 20 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 40 mg tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 20 mg tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 40 mg tadalafil
D: Arm Label: Riociguat (Adempas, BAY63-2521)_individual dose titration; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521)_individual dose titration | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Daily Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit
Brief Summary: The investigators propose to conduct a large clinical study to determine if daily bathing with chlorhexidine impregnated cloths will reduce the incidence of healthcare-associated infections in the Pediatric Intensive Care Unit (PICU).


Options:
A: Intervention Type: PROCEDURE; Name: Bathing with Chlorhexidine Impregnated Washcloths; Assigned to Arm(s): N/A
B: Arm Label: Chlorhexidine bathing; Type: EXPERIMENTAL; Interventions: Other: Chlorhexidine bathing | Arm Label: Non-chlorhexidine bathing; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-chlorhexidine bathing | Intervention Type: OTHER; Name: Chlorhexidine bathing; Assigned to Arm(s): Chlorhexidine bathing | Intervention Type: OTHER; Name: Non-chlorhexidine bathing; Assigned to Arm(s): Non-chlorhexidine bathing
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 2% Chlorhexidine gluconate cloth | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 2% Chlorhexidine gluconate cloth; Assigned to Arm(s): 1
D: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial
Brief Summary: Although there is a strong rationale to supplement gravid patients suffering intrauterine growth restriction (IUGR) or preeclampsia with Arginine or other nitric oxide donors, evidence in the literature has been inconclusive. The current study was designed to determine whether oral treatment with L-Arginine, a nitric oxide (NO) donor, would enhance birth weight and/or decrease neonatal morbidity in pregnancies with severe vascular intrauterine growth restriction (IUGR).


Options:
A: Arm Label: Sildenafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: sildenafil citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: sildenafil citrate | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: sildenafil citrate; Assigned to Arm(s): sildenafil citrate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: L ARG | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L ARG; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Sildenafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients
Brief Summary: This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 25 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: 87.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK256066; Assigned to Arm(s): 25 mcg, 87.5 mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients
Brief Summary: This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.


Options:
A: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
B: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Roflumilast; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Placebo, Roflumilast
D: Arm Label: 25 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: 87.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK256066; Assigned to Arm(s): 25 mcg, 87.5 mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality
Brief Summary: The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to placebo), on top of conventional treatment, reduces death and disease caused by the heart, the circulatory system and the kidney.

AMENDMENT 4 RATIONALE (MARCH 2012) :

Protocol amendment 4 served to address the data monitoring committee recommendation dated 14 Dec 2011 to discontinue study treatment in all participating patients. It also addressed the subsequent Health Authorities request to implement a 12 month safety follow-up period (actual duration was 9 months in average) post study drug discontinuation.


Options:
A: Arm Label: Aliskiren + Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Arm Label: Aliskiren Start - Amlodipine Add-On; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Arm Label: Amlodipine Start- Aliskiren Add-On; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On | Intervention Type: DRUG; Name: hydrochlorothiazide; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On
B: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
D: Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Drug: Losartan and hydrochlorothiazide | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrochlorothiazide switched over with Losartan at 8 weeks | Intervention Type: DRUG; Name: Losartan and hydrochlorothiazide; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Hydrochlorothiazide switched over with Losartan at 8 weeks; Assigned to Arm(s): Monotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality
Brief Summary: The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to placebo), on top of conventional treatment, reduces death and disease caused by the heart, the circulatory system and the kidney.

AMENDMENT 4 RATIONALE (MARCH 2012) :

Protocol amendment 4 served to address the data monitoring committee recommendation dated 14 Dec 2011 to discontinue study treatment in all participating patients. It also addressed the subsequent Health Authorities request to implement a 12 month safety follow-up period (actual duration was 9 months in average) post study drug discontinuation.


Options:
A: Arm Label: Aliskiren + Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Arm Label: Aliskiren Start - Amlodipine Add-On; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Arm Label: Amlodipine Start- Aliskiren Add-On; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On | Intervention Type: DRUG; Name: hydrochlorothiazide; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On
B: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
C: Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity Study of the HPV Vaccine (GSK-580299) in Healthy, Chinese, Female Subjects
Brief Summary: A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1, 6-month schedule in healthy Chinese female subjects aged 15 - 45 years.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Tetravalent Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tetravalent Vaccine | Arm Label: Bivalent Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent Vaccines | Intervention Type: BIOLOGICAL; Name: Bivalent Vaccines; Assigned to Arm(s): Bivalent Vaccine | Intervention Type: BIOLOGICAL; Name: Tetravalent Vaccine; Assigned to Arm(s): Tetravalent Vaccine
B: Arm Label: qHPV Vaccine; Type: EXPERIMENTAL; Interventions: Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: placebo (unspecified) | Intervention Type: BIOLOGICAL; Name: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): qHPV Vaccine | Intervention Type: BIOLOGICAL; Name: Comparator: placebo (unspecified); Assigned to Arm(s): Placebo
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine) | Intervention Type: BIOLOGICAL; Name: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine); Assigned to Arm(s): Cervarix Group
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and Atorvastatin in Acute Coronary Syndrome (Yokohama-ACS)
Brief Summary: The purpose of this study is to compare the effects of fluvastatin, pravastatin, pitavastatin, and atorvastatin on coronary plaque volume in patients with acute coronary syndrome, and to clarify the impact of moderate and intensive lipid lowering therapy on coronary plaque volume, serum lipids, and inflammation markers in patients with acute coronary syndrome in Japanese.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 4
B: Arm Label: EZ/Simva; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (plus simvastatin) | Arm Label: Placebo/Simva; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (plus simvastatin) | Intervention Type: DRUG; Name: ezetimibe (plus simvastatin); Assigned to Arm(s): EZ/Simva | Intervention Type: DRUG; Name: placebo (plus simvastatin); Assigned to Arm(s): Placebo/Simva
C: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
D: Arm Label: LZ group; Type: EXPERIMENTAL; Interventions: Drug: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe] | Arm Label: L group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lipitor (Atorvastatin) monotherapy | Intervention Type: DRUG; Name: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]; Assigned to Arm(s): LZ group | Intervention Type: DRUG; Name: Lipitor (Atorvastatin) monotherapy; Assigned to Arm(s): L group

Answer: A